Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication

Risk Analysis

Volumn 26, Issue 6, 2006, Pages 1471-1505

  Tebbens, Radboud J Duintjer ^a,b   Pallansch, Mark A ^c   Kew, Olen M ^c   Cáceres, Victor M ^d   Jafari, Hamid ^d   Cochi, Stephen L ^d   Sutter, Roland W ^e   Aylward, R Bruce ^e   Thompson, Kimberly M ^a,f  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b DELFT UNIVERSITY OF TECHNOLOGY   (Netherlands)

^c NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^d CENTERS FOR DIS CONTR AND PREV   (United States)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

^f MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Bioterrorism; Decision analysis; Disease outbreak; Laboratory containment; Polio eradication; Risk analysis; Vaccine associated paralytic poliomyelitis; Vaccine derived poliovirus

Indexed keywords

DECISION THEORY; DISEASES; IMMUNIZATION; STRATEGIC PLANNING; VACCINES; VIRUSES;

BIOTERRORISM; DISEASE OUTBREAK; LABORATORY CONTAINMENT; POLIO ERADICATION; VACCINE-ASSOCIATED PARALYTIC POLIOMYELITIS; VACCINE-DERIVED POLIOVIRUS;

RISK MANAGEMENT;

ORAL POLIOMYELITIS VACCINE;

HEALTH RISK; POLIOMYELITIS; RISK ASSESSMENT; VACCINE; VIRUS;

ARTICLE; EPIDEMIC; HEALTH CARE POLICY; HUMAN; IMMUNIZATION; INCOME; INFECTION RISK; MEDICAL DECISION MAKING; POLIOMYELITIS; SUPERINFECTION;

BIOTERRORISM; DISEASE OUTBREAKS; HUMANS; IMMUNIZATION PROGRAMS; LABORATORY INFECTION; MODELS, STATISTICAL; PARALYSIS; POLIOMYELITIS; POLIOVIRUS VACCINE, ORAL; PROBABILITY; RISK; RISK ASSESSMENT; TIME FACTORS; VACCINATION;

POLIOVIRUS;

EID: 33845606854     PISSN: 02724332     EISSN: 15396924     Source Type: Journal    
DOI: 10.1111/j.1539-6924.2006.00827.x     Document Type: Article

References (126)

1. Sutter, R. W., Kew, O. M., & Cochi, S. L. (2004). Poliovirus vaccine - Live. In S. A. Plotkin & W. A. Orenstein (Eds.), Vaccines, 4th ed. (p. 651-705). Philadelphia: W.B. Saunders.
2. World Health Organization. (2005). Global Polio Eradication Initiative. Available at http://www.polioeradication.org/, accessed September 26, 2005.
3. World Health Organization. (2004). Global Polio Eradication Initiative: Progress 2003. Report No.: WHO/Polio/04.01, Geneva.
4. Sangrujee, N., Duintjer Tebbens, R. J., Cáceres, V. M., & Thompson, K. M. (2003). Policy decision options during the first 5 years following certification of polio eradication. Medscape General Medicine, 5(4), 35.
5. World Health Organization. (1998). Report of the Meeting on the Scientific Basis for Stopping Polio Immunization. Report No.: WHO/EPI/GEN/98.12, Geneva: World Health Organization.
6. Wood, D. J., Sutter, R. W., & Dowdle, W. R. (2000). Stopping poliovirus vaccination after eradication: Issues and challenges. Bulletin of the World Health Organization, 78(3), 347-57.
7. Technical Consultative Group of the World Health Organization on the Global Eradication of Poliomyelitis. (2002). Endgame issues for the global polio eradication initiative. Clinical Infectious Diseases, 34, 72-79.
8. Wood, D. J. (2001). The scientific basis for stopping polio immunisation - Issues and challenges. Developments in Biologicals, 105, 69-72.
9. Cochi, S. L., Sutter, R. W., & Aylward, R. B. (2001). Possible global strategies for stopping polio vaccination and how they could be harmonized. Developments in Biologicals, 105, 153-158.
10. World Health Organization. (2003). Final report of the WHO informal consultation on identification and management of vaccine-derived polioviruses. Geneva, September 3-5.
11. World Health Organization. (2004). Global Polio Eradication Initiative: Strategic Plan 2004-2008. Geneva.
12. World Health Organization. (2004). Conclusions and recommendations of the Ad Hoc Advisory Committee on Poliomyelitis Eradication, Geneva, 21-22 September 2004. Weekly Epidemiological Record, 79(45), 401-408.
13. Aylward, R. B., & Cochi, S. L. (2004). Framework for evaluating the risks of paralytic poliomyelitis after global interruption of wild poliovirus transmission. Bulletin of the World Health Organization, 82(1), 40-46.
14. Fine, P. E. M., Sutter, R. W., & Orenstein, W. A. (2001). Stopping a polio outbreak in the post-eradication era. Developments in Biologicals, 105, 129-147.
15. Bart, K., Foulds, J., & Patriarca, P. (1996). Global eradication of poliomyelitis: Benefit-cost analysis. Bulletin of the World Health Organization, 74, 35-45.
16. Kahn, M. M., & Ehreth, J. (2003). Costs and benefits of polio eradication: A long-run global perspective. Vaccine, 21, 702-705.
17. Duintjer Tebbens, R. J., Sangrujee, N., & Thompson, K. M. (2006). The costs of future polio risk management policies. Risk Analysis, 26(6), 1507-1531.
18. Duintjer Tebbens, R. J., Pallansch, M. A., Kew, O. M., Cáceres, V. M., Sutter, R. W., & Thompson, K. M. (2005). A dynamic model of poliomyelitis outbreaks: Learning from the past to help inform the future. American Journal of Epidemiology, 162(4), 358-372.
19. Kew, O. M., Sutter, R. W., de Gourville, E., Dowdle, W. R., & Pallansch, M. A. (2005). Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annual Review of Microbiology, 59, 587-635.
20. World Bank. (2002). World Bank List of Economies (July 2002). Available at http://www.worldbank.org/data/databytopic/CLASS.XLS, accessed December 2002.
21. UNICEF. (2003). The State of the World's Children 2003. Available at http://www.unicef.org/sowc03/tables/index.html, accessed July 31, 2003.
22. Ross, S. M. (1997). Introduction to Probability Models, 6th ed. San Diego: Academic Press.
23. Alexander, L. N. (2004). Personal communication: VAPP breakdown and case-by-case characteristics. Atlanta: National Immunization Program, Centers for Disease Control and Prevention.
24. Alexander, L. N., Seward, J. F., Santibanez, T. A., Pallansch, M. A., Kew, O. M., Prevots, D. R., Strebel, P. M., Cono, J., Wharton, M., Orenstein, W. A., & Sutter, R. W. (2004). Vaccine policy changes and epidemiology of poliomyelitis in the United States. Journal of the American Medical Association, 292(14), 1696-1701.
25. Centers for Disease Control and Prevention. (2000). Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices. Morbidity and Mortality Weekly Report, 49(RR-5), 1-22.
26. Nkowane, B. M., Wassilak, S. G. F., Orenstein, W. A., Bart, K. J., Schonberger, L. B., Hinman, A. R., & Kew, O. M. (1987). Vaccine-associated paralytic poliomyelitis. United States: 1973 through 1984. Journal of the American Medical Association, 267(10), 1335-1340.
27. Strebel, P. M., Sutter, R. W., Cochi, S. L., Biellik, R. J., Brink, E. W., Kew, O. M., Pallansch, M. A., Orenstein, W. A., & Hinman, A. R. (1992). Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clinical Infectious Diseases, 14, 568-579.
28. Sutter, R. W., & Prevots, D. R. (1994). Vaccine-associated paralytic poliomyelitis among immunodeficient persons. Infections in Medicine, 11, 426-438.
29. Prevots, D. R., Sutter, R. W., Strebel, P. M., Weibel, R. E., & Cochi, S. L. (1994). Completeness of reporting for paralytic poliomyelitis, United States, 1980 through 1991. Archives of Pediatrics and Adolescent Medicine, 148, 479-485.
30. Brink, E. W. (1985). OPV Immunization and Poliovirus Antibody Prevalence Levels. Atlanta: Division of Immunization, Center for Prevention Services, Centers for Disease Control.
31. Centers for Disease Control and Prevention. (2002). Live births, birth rates, and fertility rates, by race: United States, specified years 1940-55 and each year, 1960-2000. National Vital Statistics Report, 50(5), 27.
32. Chen, R. T., Hausinger, S., Dajani, A. S., Hanfling, M., Baughman, A. L., Pallansch, M. A., & Patriarca, P. A. (1996). Seroprevalence of antibody against poliovirus in inner-city preschool children. Journal of the American Medical Association, 275(21), 1639-1645.
33. Simpson, D. M., Ezzati-Rice, T. M., & Zell, E. R. (2001). Forty years and four surveys: How does our measuring measure up? American Journal of Preventive Medicine, 20(Suppl. 4), 6-14.
34. Smith, P. Z. (2001). Personal communication: Data from: US Census Bureau, US immunization survey, national health interview survey, national immunization survey and national immunization program. Atlanta: Assessment Branch, Centers for Disease Control and Prevention.
35. Zell, E. R., Dietz, V., Stevenson, J. M., Cochi, S. L., & Bruce, R. H. (1994). Low vaccination levels of US preschool and school-age children: Retrospective assessments of vaccination coverage, 1991-1992. Journal of the American Medical Association, 271(11), 833-839.
36. Dömök, I. (1984). Experiences associated with the use of live poliovirus vaccine in Hungary, 1959-1982. Reviews of Infectious Diseases, 6(Suppl. 2), S413-S418.
37. Cáceres, V. M., & Sutter, R. W. (2001). Sabin monovalent oral polio vaccines: Review of past experiences and their potential use after polio eradication. Clinical Infectious Diseases, 33(4), 531-541.
38. World Health Organization. (2005). Poliovirus surveillance report, January-September 2005. Polio Lab Network Quarterly Update, 11(4), 3-4.
39. Centers for Disease Control and Prevention. (2004). Laboratory surveillance for wild and vaccine-derived polioviruses, January 2003-June 2004. Morbidity and Mortality Weekly Report, 53(42), 990-993.
40. Rousset, D., Rakoto-Andrianarivelo, M., Razafindratsimandresy, R., Randriamanalina, B., Guillot, S., Balanant, J., Mauclere, P., & Delpeyroux, F. (2003). Recombinant vaccine-derived poliovirus in Madagascar. Emerging Infectious Diseases, 9(7), 885-887.
41. Shimizu, H., Thorley, B., Paladin, F. J., Brussen, K. A., Stambos, V., Yuen, L., Utama, A., Tano, Y., Arita, M., Yoshida, H., Yoneyama, T., Benegas, A., Roesel, S., Pallansch, M. A., Kew, O. M., & Miyamura, T. (2004). Circulation of type 1 vaccine-derived poliovirus in the Philippines in 2001. Journal of Virology, 78(24), 13512-13521.
42. Kew, O., Morris-Glasgow, V., Landaverde, M., Burns, C., Shaw, J., Garib, Z., Andre, J., Blackman, E., Freeman, C. J., Jorba, J., Sutter, R., Tambini, G., Venezel, L., Pedreira, C., Laender, F., Shimizu, H., Yoneyama, T., Miyamura, T., van Der Avoort, H., Oberste, M. S., Kilpatrick, D., Cochi, S., Pallansch, M., & de Quadros, C. (2002). Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science, 296(5566), 356-359.
43. Yang, C., Naguib, T., Yang, S., Nasr, E., Jorba, J., Ahmed, N., Campagnoli, R., van der Avoort, H., Shimizu, H., Yoneyama, T., Miyamura, T., Pallansch, M. A., & Kew, O. M. (2003). Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993. Journal of Virology, 77(15), 8366-8877.
44. Centers for Disease Control and Prevention. (2003). Laboratory surveillance for wild and vaccine-derived polioviruses, January 2002-June 2003. Morbidity and Mortality Weekly Report, 52(38), 913-916.
45. Park, R. E., Yang, C-F, Yang, S.-J, Campagnoli, R. P., Asghar, H., Nategh, R., & Kew, O. M. (2002). Molecular characterization of divergent Sabin 2-derived isolates from patients with paralysis. Presented at the 21st Annual Meeting of the American Society for Virology July 18, 2002, Lexington, KY.
46. Georgescu, M.-M, Balanant, J., Macadam, A., Otelea, D., Combiescu, M., Combiescu, A. A., Crainic, R., & Delpeyroux, F. (1997). Evolution of the Sabin type 1 poliovirus in humans: Characterization of strains isolated from patients with vaccine-associated paralytic poliomyelitis. Journal of Virology, 71(10), 7758-7768.
47. Centers for Disease Control and Prevention. (2002). Laboratory surveillance for wild poliovirus and vaccine-derived poliovirus, 2000-2001. Morbidity and Mortality Weekly Report, 51(17), 369-371.
48. Centers for Disease Control and Prevention. (2005). Poliovirus infections in four unvaccinated children - Minnesota, August-October 2005. Morbidity and Mortality Weekly Report, 54(Dispatch), 1-3.
49. Chiba, Y., Kobayashi, M., Chosa, T., Yamamoto, T., Endo, K., Shimizu, H., Li, L., Wen-Bo, X., & Zhang, L.-B. (2003). Molecular epidemiology of type 2 vaccine-associated paralytic poliomyelitis in China. Japanese Journal of Infectious Diseases, 56, 181-183.
50. Martín, J., Odoom, K., Tuite, G., Dunn, G., Hopewell, N., Cooper, G., Fitzharris, C., Butler, K., Hall, W. W., & Minor, P. D. (2004). Long-term excretion of vaccine-derived poliovirus by a healthy child. Journal of Virology, 78(24), 13839-13847.
51. Cherkasova, E. A., Korotkova, E. A., Yakovenko, M. L., Ivanova, O. E., Eremeeva, T. P., Chumakov, K. M., & Agol, V. I. (2002). Long-term circulation of vaccine-derived poliovirus that causes paralytic disease. Journal of General Virology, 76(23), 6791-6799.
52. Cherkasova, E., Laassri, M., Chizhikov, V., Korotkova, E., Dragunsky, E., Agol, V. I., & Chumakov, K. (2003). Microarray analysis of evolution of RNA viruses: Evidence of circulation of virulent highly divergent vaccine-derived polioviruses. Proceedings of the National Academy of Sciences of the United States of America, 100(16), 9398-9403.
53. Horie, H., Yoshida, H., Matsuura, K., Miyazawa, M., Wakabayashi, K., Nomoto, A., & Hashizume, S. (2002). Isolation of vaccine-derived type 1 polioviruses displaying similar properties to virulent wild strain Mahoney from sewage in Japan. Journal of Medical Virology, 68(3), 445-451.
54. Yoshida, H., Horie, H., Matsuura, K., Kitamura, T., Hashizume, S., & Miyamura, T. (2002). Prevalence of vaccine-derived polioviruses in the environment. Journal of General Virology, 83(Pt 5), 1107-1111.
55. Martín, J., Ferguson, G. L., Wood, D. J., & Minor, P. D. (2000). The vaccine origin of the 1968 epidemic of type 3 poliomyelitis in Poland. Virology, 278, 42-49.
56. Korotkova, E. A., Park, R., Cherkasova, E. A., Lipskaya, G. Y., Chumakov, K. M., Feldman, E. V., Kew, O. M., & Agol, V. I. (2003). Retrospective analysis of a local cessation of vaccination against poliomyelitis: A possible scenario for the future. Journal of Virology, 77(23), 12460-12465.
57. Pavlov, D. N., Van Zyl, W. B., Kruger, M., Blignaut, L., Grabow, W. O. K., & Ehlers, M. M. (2006). Poliovirus vaccine strains detected in stool specimens of immunodeficient children in South Africa. Diagnostic Microbiology and Infectious Diseases, 54(1), 23-30.
58. Pavlov, D. N., Van Zyl, W. B., Van Heerden, J., Grabow, W. O. K., & Ehlers, M. M. (2005). Prevalence of vaccine-derived polioviruses in sewage and river water in South Africa. Water Research, 39(14), 3309-3319.
59. Kew, O. M., Wright, P. F., Agol, V. I., Delpeyroux, F., Shimizu, H., Nathanson, N., & Pallansch, M. A. (2004). Circulating vaccine-derived polioviruses: Current state of knowledge. Bulletin of the World Health Organization, 82(1), 16-23.
60. Más Lago, P. (1999). Eradication of poliomyelitis in Cuba: A historical perspective. Bulletin of the World Health Organization, 77(8), 681-687.
61. Strebel, P. M., Aubert-Combiescu, A., Ion-Nedelcu, N., Biberi-Moroeanu, S., Combiescu, M., Sutter, R. W., Kew, O. M., Pallansch, M. A., Patriarca, P. A., & Cochi, S. L. (1994). Paralytic poliomyelitis in Romania, 1984-1992. Evidence for a high risk of vaccine-associated disease and reintroduction of wild-virus infection. American Journal of Epidemiology, 140, 1111-1124.
62. Más Lago, P., Gary, H. E., Jr., Pérez, L. S., Cáceres, V. M., Olivera, J. B., Puentes, R. P., Corredor, M. B., Jimenez, P., Pallansch, M. A., & González Cruz, R. (2003). Poliovirus detection in wastewater and stools following an immunization campaign in Havana, Cuba. International Journal of Epidemiology, 32, 772-777.
63. Más Lago, P., Cáceres, V. M., Galindo, M. A., Gary, H. E., Jr., Valcarcel, M., Barrios, J., Sarmienro, L., Avalos, I., Bravo, J. A., Palomera, R., Bello, M., Sutter, R. W., Pallansch, M. A., & de Quadros, C. A. (2001). Persistence of vaccine-derived poliovirus following a mass vaccination campaign in Cuba: Implications for stopping polio vaccination after global eradication. International Journal of Epidemiology, 30, 1029-1034.
64. Más Lago, P., Bravo, J. R., Andrus, J. K., Comellas, M. M., Galindo, M. A., de Quadros, C. A., & Bell, E. (1994). Lesson from Cuba: Mass campaign administration of trivalent oral poliovirus vaccine and seroprevalence of poliovirus neutralizing antibodies. Bulletin of the World Health Organization, 72(2), 221-225.
65. Onorato, I. M., Modlin, J. F., McBean, M. A., Thoms, M. L., Losonsky, G. A., & Bernier, R. H. (1991). Mucosal immunity induced by enhanced-potency inactivated and oral polio vaccines. Journal of Infectious Diseases, 163, 1-6.
66. Modlin, J. F., Halsey, N. A., Thoms, M. L., Meschievitz, C. K., & Patriarca, P. A. (1997). Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine-live attenuated oral poliovirus vaccine immunization schedules. Baltimore area polio vaccine study group. Journal of Infectious Diseases, 175(Suppl. 1), s228-s234.
67. Ghendon, Y. Z., & Sanakoyeva, I. I. (1961). Comparison of the resistance of the intestinal tract to poliomyelitis virus (sabin's strains) in persons after naturally and experimentally acquired immunity. Acta Virologica, 5, 265-273.
68. Huang, S. Q., Greening, G., Baker, M., Grimwood, K., Hewitt, J., Hulston, D., van Duin, L., Fitzsimons, A., Graham, D., Lennon, D., Shimizu, H., Miyamura, T., & Pallansch, M. A. (2005). Persistence of oral polio vaccine virus after its removal from the immunisation schedule in New Zealand. Lancet, 366(9483), 394-396.
69. UN Population Division. (2003). World Population Prospects Population Database: The 2002 Revision Population Database. Available at http://esa.un.org/unpp/index.asp?panel=2, accessed July 31, 2003.
70. Halsey, N. A., Pinto, J., Espinosa-Rosales, F., Faure-Fontenla, M., da Silva, E. E., Kahn, A. A., ADB, W., Minor, P. D., Dunn, G., Asturia, E., Hussain, H., Pallansch, M. A., & Kew, O. M. (2004). Search for polio virus carriers among people with primary immune deficiency diseases in the United States, Mexico, Brazil and the United Kingdom. Bulletin of the World Health Organization, 82(1), 3-8.
71. Khetsuriani, N., Prevots, D. R., Quick, L., Elder, M. E., Pallansch, M. A., Kew, O. M., & Sutter, R. W. (2003). Persistence of vaccine-derived polioviruses among immunodeficient persons with vaccine-associated paralytic poliomyelitis. Journal of Infectious Diseases, 188, 1845-1852.
72. Fiore, L., Plebani, A., Buttinelli, G., Fiore, S., Donati, V., Marturano, J., Soresina, A., Martire, B., Azzari, C., Nigro, G., Cardinale, F., Trizzino, A., Pignata, C., Alvisi, P., Anastasio, E., Bossi, G., & Ugazio, A. G. (2004). Search for poliovirus long-term excretors among patients affected by agammaglobulinemia. Clinical Immunology, 111(1), 98-102.
73. MacLennan, C., Dunn, G., Huissoon, A. P., Kumararatne, D. S., Martin, J., O'Leary, P., Thompson, R. A., Osman, H., Wood, P., Minor, P., Wood, D. J., & Pillay, D. (2004). Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man. Lancet, 363(9420), 1509-1513.
74. Bellmunt, A., May, G., Zell, R., Pring-Akerblom, P., Verhagen, W., & Heim, A. (1999). Evolution of poliovirus type i during 5.5 years of prolonged enteral replication in an immunodeficient patient. Virology, 265(2), 178-184.
75. Kew, O. M., Sutter, R. W., Nottay, B. K., McDonough, M. J., Prevots, D. R., Quick, L., & Pallansch, M. A. (1998). Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient. Journal of Clinical Microbiology, 36(10), 2893-2899.
76. Cernakova, B., Sobotova, Z., Rovny, I., Blahova, S., Roivainen, M., & Hovi, T. (2005). Isolation of vaccine-derived polioviruses in the Slovak Republic. European Journal of Clinical Microbiology and Infectious Diseases, 24(6), 438-439.
77. Blomqvist, S., Savolainen, C., Laine, P., Hirttio, P., Lamminsalo, E., Penttila, E., Joks, S., Roivainen, M., & Hovi, T. (2004). Characterization of a highly evolved vaccine-derived poliovirus type 3 isolated from sewage in Estonia. Journal of Virology, 78(9), 4876-4883.
78. Shulman, L. M., Manor, Y., Handsher, R., Delpeyroux, F., McDonough, M. J., Halmut, T., Silberstein, T., Alfandari, J., Quay, J., Fisher, T., Robinov, J., Kew, O. M., Crainic, R., & Mendelson, E. (2000). Molecular and antigenic characterization of a highly evolved derivative of the type 2 oral poliovaccine strain isolated from sewage in Israel. Journal of Clinical Microbiology, 38(10), 3729-3734.
79. Western Pacific Regional Office. (2005). Basic Health Information on Poliomyelitis (Revised as of 06 December 2005). Available at http://www.wpro.who.int/information_sources/databases/regional_statistics/ rstat_poliomyelitis.htm, accessed January 19, 2006.
80. Tharmaphornpilas, P. (2005). Vaccine-derived poliovirus, Thailand, 2003. Emerging Infectious Diseases, 11(5), 777-778.
81. Yang, C.-F., Chen, H.-Y., Jorba, J., Sun, H.-C., Yang, S.-J., Lee, H.-C., Huang, Y.-C., Lin, T.-Y., Chen, P.-J., Shimizu, H., Nishimura, Y., Utama, A., Pallansch, M. A., Miyamura, T., Kew, O. M., & Yang, J.-Y. (2005). Intratypic recombination among lineages of type 1 vaccine-derived poliovirus emerging during chronic infection of an immunodeficient patient. Journal of Virology, 79(20), 12623-12634.
82. Hidalgo, S., Garcia, E. M., Cisterna, D., & Freire, M. C. (2003). Paralytic poliomyelitis caused by a vaccine-derived polio virus in an antibody-deficient argentinean child. Pediatric Infectious Diseases Journal, 22(6), 570-572.
83. Misbah, S. A., Lawrence, P. A., Kurtz, J. B., & Chapel, H. M. (1991). Prolonged faecal excretion of poliovirus in a nurse with common variable hypogammaglobulinaemia. Postgraduate Medical Journal, 67(785), 301-303.
84. Abo, W., Chiba, S., Yamanaka, T., Nakao, T., Hara, M., & Tagaya, I. (1979). Paralytic poliomyelitis in a child with agammaglobulinemia. European Journal of Pediatrics, 132(1), 11-16.
85. Hara, M., Saito, Y., Komatsu, T., Kodama, H., Abo, W., Chiba, S., & Nakao, T. (1981). Antigenic analysis of polioviruses isolated from a child with agammaglobulinemia and paralytic poliomyelitis after Sabin vaccine administration. Microbiology and Immunology, 25(9), 905-913.
86. Labadie, K., Pelletier, I., Saulnier, A., Martín, J., Colbere-Garapin, F. (2004). Poliovirus mutants excreted by a chronically infected hypogammaglobulinemic patient establish persistent infections in human intestinal cells. Virology, 318(1), 66-78.
87. Martín, J., Dunn, G., Hull, R., Patel, V., & Minor, P. D. (2000). Evolution of the Sabin strain of type 3 poliovirus in an immunodeficient patient during the entire 637-day period of virus excretion. Journal of Virology, 74(7), 3001-3010.
88. MacCallum, F. O. (1971). Hypogammaglobulinaemia in the United Kingdom. VII. The role of humoral antibodies in protection against and recovery from bacterial and virus infections in hypogammaglobulinaemia. Medical Research Council Special Report Series, 310, 72-85.
89. Minor, P. D. (2001). Characteristics of poliovirus strains from long-term excretors with primary immunodeficiencies. Developments in Biologicals, 105, 75-80.
90. Dowdle, W. R., de Gourville, E., Kew, O. M., Pallansch, M. A., & Wood, D. J. (2003). Polio eradication: The OPV paradox. Reviews in Medical Virology, 13, 277-291.
91. Kew, O. M., Mulders, M. N., Lipskaya, G. Y., da Silva, E. E., & Pallansch, M. A. (1995). Molecular epimdemiology of polioviruses. Seminars in Virology, 6, 401-414.
92. Fine, P. E. M., & Carneiro, I. A. M. (1999). Transmissibility and persistence of oral poliovirus vaccine viruses: Implications for the global poliomyelitis eradication initiative. American Journal of Epidemiology, 150(10), 1001-1021.
93. Dowdle, W. R., & Birmingham, M. E. (1997). The biologic principles of poliovirus eradication. Journal of Infectious Diseases, 175(Suppl. 1), S286-S292.
94. Dowdle, W. R., Gary, H. E., Sanders, R., & van Loon, A. M. (2002). Can post-eradication laboratory containment of wild polioviruses be achieved? Bulletin of the World Health Organization, 80(4), 311-316.
95. World Health Organization. (2004). WHO Global Action Plan for Laboratory Containment of Wild Polioviruses, 2nd ed. Report No.: WHO/V&B/03.11, Geneva: World Health Organization.
96. Mulders, M. N., Reimerink, J. H., Koopmans, M. P., van Loon, A. M., & van der Avoort, H. G. A. M. (1997). Genetic analysis of wild-type poliovirus importation into the Netherlands (1979-1995). Journal of Infectious Diseases, 176(3), 617-624.
97. Deshpande, J. M., Nadkarni, S. S., & Siddiqui, Z. A. (2003). Detection of MEF-1 laboratory reference strain of poliovirus type 2 in children with poliomyelitis in India in 2002 & 2003. Indian Journal of Medical Research, 118, 217-223.
98. Dowdle, W. R., Wolff, C., Sanders, R., Lambert, S., & Best, M. (2004). Will containment of wild poliovirus in laboratories and inactivated poliovirus vaccine production sites be effective for global certification? Bulletin of the World Health Organization, 82(1), 59-62.
99. Plotkin, S. A., & Vidor, E. (2004). Poliovirus vaccine - Inactivated. In S. A. Plotkin & W. A. Orenstein (Eds.) Vaccines, 4th ed. (pp. 625-649). Philadelphia: WB Saunders.
100. Centers for Disease Control and Prevention. (2006). Resurgence of wild poliovirus type 1 transmission and consequences of importation - 21 previously polio-free countries, 2002-2005. Morbidity and Mortality Weekly Report, 55(6), 145-150.
101. Smith, J., Leke, R., Adams, A., & Tangermann, R. H. (2004). Certification of polio eradication: Process and lessons learned. Bulletin of the World Health Organization, 82(1), 24-29.
102. World Health Organization. (2005). Progress towards poliomyelitis eradication-poliomyelitis outbreak in Sudan, 2004. Weekly Epidemiological Record, 80(5), 42-46.
103. Sutter, R. W. (2002). Global burden estimate of vaccine-associated paralytic poliomyelitis (VAPP). Presented at the WHO Informal Consultation on Research Towards Development of Post-Certification Immunization Policy October 31-November 1, 2002. Geneva, Switzerland.
104. John, T. J. (2002). Vaccine-associated paralytic polio in India. Bulletin of the World Health Organization, 80(11), 917.
105. Plotkin, S. A. (2001). Commentary: Cuba libre de poliovirus. International Journal of Epidemiology, 30, 1034.
106. Rümke, H., Oostvogel, P. M., van Steenis, G., & van Loon, A. M. (1995). Poliomyelitis in the Netherlands: A review of population immunity and exposure between the epidemics in 1978 and 1992. Epidemiology and Infection, 115(2), 289-298.
107. Cooke, R. M. (1991). Experts in Uncertainty: Opinion and Subjective Probability in Science. New York: Oxford University Press.
108. Thompson, K. M., & Graham, J. D. (1996). Going beyond the single number: Using probabilistic risk assessment to improve risk management. Human and Ecological Risk Assessment, 2(4), 1008-1034.
109. Thompson, K. M., & Duintjer Tebbens, R. J. (2006). Evaluation of response scenarios to potential polio outbreaks using mathematical models. Risk Analysis, 26(6), 1541-1556.
110. Fine, P. E. M., Oblapenko, G., & Sutter, R. W. (2004). Polio control after certification: Major issues outstanding. Bulletin of the World Health Organization, 82(1), 47-52.
111. Sangrujee, N., Cáceres, V. M., & Cochi, S. L. (2004). Cost analysis of post-polio certification immunization policies. Bulletin of the World Health Organization, 82(1), 9-15.
112. Kohler, K. A., Banerjee, K., Gary Hlady, W., Andrus, J. K., & Sutter, R. W. (2002). Vaccine-associated paralytic poliomyelitis in India during 1999: Decreased risk despite massive use of oral polio vaccine. Bulletin of the World Health Organization, 80(3), 210-216.
113. Joce, R., Wood, D., Brown, D., & Begg, N. (1992). Paralytic poliomyelitis in England and Wales, 1985-91. British Medical Journal, 305(6845), 69-70.
114. Strebel, P. M., Ion-Nedelcu, N., Baughman, A. L., Sutter, R. W., & Cochi, S. L. (1995). Intramuscular injections within 30 days of immunization with oral poliovirus vaccine - A risk factor for vaccine-associated paralytic poliomyelitis. New England Journal of Medicine, 332, 500-506.
115. Andrus, J. K., Strebel, P. M., de Quadros, C. A., & Olivé, J. M. (1995). Risk of vaccine-associated paralytic poliomyelitis in Latin America, 1989-91. Bulletin of the World Health Organization, 73(1), 33-40.
116. Esteves, K. (1988). Safety of oral poliomyelitis vaccine: Results of a WHO enquiry. Bulletin of the World Health Organization, 66, 739-746.
117. John, T. J. (2004). A developing country perspective on vaccine-associated paralytic poliomyelitis. Bulletin of the World Health Organization, 82(1), 53-57.
118. Patriarca, P. A., Wright, P. F., & John, T. J. (1991). Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: Review. Reviews of Infectious Diseases, 13, 926-939.
119. Kohler, K. A., Banerjee, K., & Sutter, R. W. (2002). Further clarity on vaccine-associated paralytic polio in India (letter). Bulletin of the World Health Organization, 80(12), 987.
120. Cohen-Abbo, A., Culley, B. S., Reed, G. W., Sannella, E. C., Mace, R. L., Robertson, S. E., & Wright, P. F. (1994). Seroresponse to trivalent oral poliovirus vaccine as a function of dosage interval. Pediatric Infectious Diseases Journal, 14(2), 100-106.
121. Fine, P. E. M. (1993). Herd immunity: History, theory, practice. Epidemiologic Reviews, 15(2), 265-302.
122. Hennessey, K. A., Lago, H., Diomande, F., Akoua-Koffi, C., Cáceres, V. M., Pallansch, M. A., Kew, O. M., Nolan, M., & Zuber, P. L. (2005). Poliovirus vaccine shedding among persons with HIV in Abidjan, Cote d'Ivoire. Journal of Infectious Diseases, 192(12), 2124-2128.
123. Fine, P. E. M., & Carneiro, I. A. M. (1998). Transmissibility and Persistence of Oral Poliovirus Vaccine Viruses: Implications for the Global Poliomyelitis Eradication Initiative. London: Infectious Disease Epidemiology Unit, Department of Infectious and Tropical Diseases, London School of Hygiene.
124. Patriarca, P. A., Sutter, R. W., & Oostvogel, P. M. (1997). Outbreaks of paralytic poliomyelitis, 1976-1995. Journal of Infectious Diseases, 175(Suppl. 1), S165-S172.
125. Equipe de dynamique des populations bactériennes. (2004). Binomial Confidence Interval. Laboratoire de Biométrie et Bioligie Evolutive, Université de Lyon. Available at http://umr5558-sud-str3.univ-lyon1.fr- bici-, accessed April 13, 2004.
126. Gelman, A. B., Carlin, J. B., Stern, H. S., & Rubin, D. B. (2000). Bayesian Data Analysis. Boca Raton, FL: Chapman & Hall/CRC.